3 Fr Neonatal and paediatric Multicath 2

Product Description

Rifampicin-Miconazole supersaturated CVCs have demonstrated the potential to prevent catheter-associatedcolonization, local infection and bloodstream infection even in long-term application. (4)The combination of Rifampicin and Miconazole leads to protection against a broad spectrum of microorganismssuch as Staphylococci, Enterobacterial and Candida. (5) The use of a rifampicin-miconazole-impregnated catheter (RM-C) has been suggested to have the greatestbenefit in femoral access. (6)

A pharmacokinetic analysis conducted by Rump concluded that Maximal concentrations of Rifampicin orMiconazole resulting from the insertion of a polyurethane catheter loaded with these antibiotics are therefore,far below the concentrations resulting from a systemic therapy with the same antimicrobial agents. Even in theworst case, the danger of selecting resistant bacterial strains seems remote because the systemic drug  levels aremagnitudes of order below subinhibitory concentrations. (7)